Published in Cancer Weekly, September 9th, 2003
The finding comes from a study published in the October 1, 2003, issue of Cancer, and provides the first evidence that clinical trials offer cost-effective treatments for non-small-cell lung cancer.
Lung cancer is the leading cause of cancer-related death in the United States, with 5-year survival rates of only 14%, a rate that has remained largely unchanged for decades, pointing to the limitations of current treatment modalities. Non-small-cell lung cancer is the most common type, accounting for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.